Global Generics & Biosimilars Industry Sets Out Vision To 2030
The IGBA Has Identified Seven Key Actions Necessary For Industry
Executive Summary
Headwinds as well as opportunities for the off-patent industry are discussed in a comprehensive new whitepaper by the International Generic and Biosimilar Medicines Association
You may also be interested in...
Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.